Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial
Academic Article
Publication Date:
2015
abstract:
A novel oral octreotide formulation was tested for efficacy and safety in a phase III, multicenter, open-label, dose-titration, baseline-controlled study in patients with acromegaly.
Iris type:
1.1 Articolo in rivista
Keywords:
Acromegaly; Adenoma; Administration; Oral; Adult; Aged; Antineoplastic Agents; Hormonal; Dose-Response Relationship; Drug; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide; Treatment Outcome
List of contributors:
Melmed, Shlomo; Popovic, Vera; Bidlingmaier, Martin; Mercado, Moises; van der Lely Aart, Jan; Biermasz, Nienke; Bolanowski, Marek; Coculescu, Mihail; Schopohl, Jochen; Racz, Karoly; Glaser, Benjamin; Goth, Miklos; Greenman, Yona; Trainer, Peter; Mezosi, Emese; Shimon, Ilan; Giustina, Andrea; Korbonits, Márta; Bronstein Marcello, D; Kleinberg, David; Teichman, Sam; Gliko Kabir, Irit; Mamluk, Roni; Haviv, Asi; Strasburger, Christian
Published in: